百利天恒H1转亏 正拟定增募不超37.6亿2023上市募10亿

Core Viewpoint - 百利天恒 reported significant declines in revenue and net profit for the first half of 2025, indicating financial challenges faced by the company [1] Financial Performance - For the first half of 2025, 百利天恒 achieved operating revenue of 171 million yuan, a year-on-year decrease of 96.92% [1] - The net profit attributable to shareholders was -1.118 billion yuan, compared to 4.666 billion yuan in the same period last year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -1.176 billion yuan, down from 4.644 billion yuan year-on-year [1] - The net cash flow from operating activities was -1.134 billion yuan, compared to 5.029 billion yuan in the previous year [1] - In 2024, the company reported a net profit of 3.708 billion yuan, recovering from a loss of 780 million yuan in the previous year [1] Fundraising and Stock Issuance - 百利天恒 raised a total of 990.47 million yuan from its initial public offering, with a net amount of 884.40 million yuan, which was 537.88 million yuan less than originally planned [2] - The company intended to raise 1.422 billion yuan for antibody drug industrialization and clinical research projects [2] - The total issuance costs (excluding VAT) amounted to 106.07 million yuan, with underwriting fees of 79 million yuan [2] Regulatory Approvals - On July 14, 2025, 百利天恒 received approval from the Shanghai Stock Exchange for its application to issue shares to specific investors [2] - The company announced on August 8, 2025, that it received approval from the China Securities Regulatory Commission for its registration application to issue shares to specific investors [3]